Prelude Capital Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Prelude Capital Management’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-6,600	Closed	-$204K	–	1321
2022 Q3	$204K	Hold	6,600	–	–	0.01%	1066
2022 Q2	$208K	Hold	6,600	–	–	0.01%	1272
2022 Q1	$303K	Sell	6,600 -800	-11%	-$38.1K	0.01%	1074
2021 Q4	$453K	Sell	7,400 -11,800	-61%	-$816K	0.01%	1074
2021 Q3	$1.44M	Buy	19,200 +5,700	+42%	+$478K	0.04%	421
2021 Q2	$1.25M	Sell	13,500 -1,600	-11%	-$136K	0.04%	497
2021 Q1	$1.34M	Buy	15,100 +11,500	+319%	+$1.14M	0.03%	490
2020 Q4	$336K	Buy	3,600 +2,800	+350%	+$223K	0.01%	870
2020 Q3	$51K	Buy	+800	New	+$46.9K	﹤0.01%	1112

Other funds holding ARKG

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Prelude Capital Management's ARKG Position: Q1 2026 in Review

Prelude Capital Management sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2026, closing a stake of 76,000 shares — an estimated $2.2M sold.

Prelude Capital Management first reported a position in ARKG in Q4 2025 and held it in 1 quarter. The position peaked at $2.2M in Q4 2025. 218 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.

Prelude Capital Management reported no remaining ARK Genomic Revolution ETF position as of Q1 2026 after selling out during the quarter.
Prelude Capital Management sold 76,000 ARK Genomic Revolution ETF shares in Q1 2026, an estimated $2.2M.
Prelude Capital Management first reported a position in ARK Genomic Revolution ETF in Q4 2025 and held it in 1 quarter.
Prelude Capital Management's ARK Genomic Revolution ETF position peaked at $2.2M in Q4 2025.
218 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.